Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive impairment associated with Huntington's disease, spelling the end of the program.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,